News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) Invests $18.6 Million in Amicus Therapeutics, Inc. (FOLD) to Expand Fabry Disease Drug Deal


7/18/2012 7:44:35 AM

GlaxoSmithKline has made an additional $18.6 million investment in Amicus Therapeutics as part of an expansion to the firms’ collaboration on development of Amicus’ pharmacological chaperone migalastat HCL (AT1001) for the treatment of Fabry disease. The investment by GSK, at $6.3 per share of common stock, means the firm now owns 19.9% of Amicus. The latter will also receive a $3.5 million milestone cash payment from GSK relating to achievement of a clinical development milestone earlier this year.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES